Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zanni

Showing results (891-900 of 943) with videos related to

Pageof 95
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 27, 2025
Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE TrialMichael J Corley, Maya Watanabe, Alina P S Pang, et al.
AIDS (London, England)|July 24, 2025
No evidence of pitavastatin effect on muscle area or density among people with HIVKristine M Erlandson, Triin Umbleja, Heather J Ribaudo, et al.
Contemporary Clinical Trials|December 3, 2022
The importance of methods for site performance evaluation in REPRIEVE, a longitudinal, global, multicenter trialEvelynne S Fulda, Carl J Fichtenbaum, Emma M Kileel, et al.
The Lancet. HIV|April 5, 2026
Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysisTriin Umbleja, Mohammad U Zafar, Sara McCallum, et al.
JAMA Network Open|June 29, 2021
Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular PreventionUdo Hoffmann, Michael T Lu, Borek Foldyna, et al.
JACC. Advances|August 21, 2025
Frailty, Pitavastatin, and Major Adverse Cardiovascular Events Among People With HIVKristine M Erlandson, Ariela R Orkaby, Triin Umbleja, et al.
The Journal of Infectious Diseases|July 10, 2020
Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE TrialCarl J Fichtenbaum, Heather J Ribaudo, Jorge Leon-Cruz, et al.
Hematological Oncology|May 13, 2025
Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a "Fondazione Italiana Linfomi" Cohort StudyAlberto Bavieri, Sara Veronica Usai, Michele Merli, et al.
American Heart Journal|April 1, 2019
Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkersUdo Hoffmann, Michael T Lu, Devvora Olalere, et al.
The Lancet. Haematology|December 28, 2020
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trialMarco Ladetto, Sergio Cortelazzo, Simone Ferrero, et al.
Pageof 95

Showing results (891-900 of 943) with videos related to

Sort By:
Pageof 95
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 27, 2025
Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE TrialMichael J Corley, Maya Watanabe, Alina P S Pang, et al.
AIDS (London, England)|July 24, 2025
No evidence of pitavastatin effect on muscle area or density among people with HIVKristine M Erlandson, Triin Umbleja, Heather J Ribaudo, et al.
Contemporary Clinical Trials|December 3, 2022
The importance of methods for site performance evaluation in REPRIEVE, a longitudinal, global, multicenter trialEvelynne S Fulda, Carl J Fichtenbaum, Emma M Kileel, et al.
The Lancet. HIV|April 5, 2026
Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysisTriin Umbleja, Mohammad U Zafar, Sara McCallum, et al.
JAMA Network Open|June 29, 2021
Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular PreventionUdo Hoffmann, Michael T Lu, Borek Foldyna, et al.
JACC. Advances|August 21, 2025
Frailty, Pitavastatin, and Major Adverse Cardiovascular Events Among People With HIVKristine M Erlandson, Ariela R Orkaby, Triin Umbleja, et al.
The Journal of Infectious Diseases|July 10, 2020
Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE TrialCarl J Fichtenbaum, Heather J Ribaudo, Jorge Leon-Cruz, et al.
Hematological Oncology|May 13, 2025
Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a "Fondazione Italiana Linfomi" Cohort StudyAlberto Bavieri, Sara Veronica Usai, Michele Merli, et al.
American Heart Journal|April 1, 2019
Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkersUdo Hoffmann, Michael T Lu, Devvora Olalere, et al.
The Lancet. Haematology|December 28, 2020
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trialMarco Ladetto, Sergio Cortelazzo, Simone Ferrero, et al.
Pageof 95